pmv pharmaceuticals inc - PMVP

PMVP

Close Chg Chg %
1.22 0.03 2.46%

Closed Market

1.25

+0.03 (2.46%)

Volume: 327.30K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: pmv pharmaceuticals inc - PMVP

PMVP Key Data

Open

$1.22

Day Range

1.22 - 1.29

52 Week Range

0.81 - 1.84

Market Cap

$64.92M

Shares Outstanding

53.21M

Public Float

43.80M

Beta

1.64

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.58

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

264.64K

 

PMVP Performance

1 Week
 
0.81%
 
1 Month
 
-5.30%
 
3 Months
 
-13.19%
 
1 Year
 
-17.22%
 
5 Years
 
-97.97%
 

PMVP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About pmv pharmaceuticals inc - PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

PMVP At a Glance

PMV Pharmaceuticals, Inc.
400 Alexander Park Drive
Princeton, New Jersey 08540
Phone 1-609-642-6670 Revenue 0.00
Industry Biotechnology Net Income -58,709,000.00
Sector Health Technology Employees 47
Fiscal Year-end 12 / 2025
View SEC Filings

PMVP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.445
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 1.072
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.013

PMVP Efficiency

Revenue/Employee N/A
Income Per Employee -1,249,127.66
Receivables Turnover N/A
Total Asset Turnover N/A

PMVP Liquidity

Current Ratio 12.224
Quick Ratio 12.224
Cash Ratio 11.792

PMVP Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -26.479
Return on Equity -29.225
Return on Total Capital -33.118
Return on Invested Capital -28.291

PMVP Capital Structure

Total Debt to Total Equity 0.676
Total Debt to Total Capital 0.671
Total Debt to Total Assets 0.622
Long-Term Debt to Equity 0.476
Long-Term Debt to Total Capital 0.473
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pmv Pharmaceuticals Inc - PMVP

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
1.28M 650.00K 1.26M 1.14M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.28M 650.00K 1.26M 1.14M
Depreciation
1.28M 650.00K 1.26M 1.14M
Amortization of Intangibles
- - - -
-
COGS Growth
+302.83% -49.26% +93.38% -8.99%
Gross Income
(1.28M) (650.00K) (1.26M) (1.14M)
Gross Income Growth
-302.83% +49.26% -93.38% +8.99%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
57.01M 76.39M 78.88M 84.30M
Research & Development
36.19M 51.67M 54.63M 57.38M
Other SG&A
20.83M 24.72M 24.25M 26.92M
SGA Growth
+64.66% +33.99% +3.25% +6.88%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(58.29M) (77.04M) (80.13M) (85.45M)
Non Operating Income/Expense
470.00K 3.71M 11.17M 10.64M
Non-Operating Interest Income
449.00K 3.63M 11.17M 10.65M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(57.82M) (73.33M) (68.96M) (74.81M)
Pretax Income Growth
-67.92% -26.81% +5.96% -8.48%
Pretax Margin
- - - -
-
Income Tax
23.00K (9.00K) 2.00K (16.10M)
Income Tax - Current - Domestic
- (9.00K) 2.00K (16.17M)
Income Tax - Current - Foreign
- - - 70.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(57.85M) (73.32M) (68.96M) (58.71M)
Minority Interest Expense
- - - -
-
Net Income
(57.85M) (73.32M) (68.96M) (58.71M)
Net Income Growth
-67.96% -26.75% +5.94% +14.87%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(57.85M) (73.32M) (68.96M) (58.71M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(57.85M) (73.32M) (68.96M) (58.71M)
EPS (Basic)
-1.2816 -1.608 -1.4362 -1.1382
EPS (Basic) Growth
-66.64% -25.47% +10.68% +20.75%
Basic Shares Outstanding
45.14M 45.59M 48.01M 51.58M
EPS (Diluted)
-1.2816 -1.608 -1.4362 -1.1382
EPS (Diluted) Growth
-66.64% -25.47% +10.68% +20.75%
Diluted Shares Outstanding
45.14M 45.59M 48.01M 51.58M
EBITDA
(57.01M) (76.39M) (78.88M) (84.30M)
EBITDA Growth
-64.66% -33.99% -3.25% -6.88%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 7.60
Number of Ratings 5 Current Quarters Estimate -0.333
FY Report Date 03 / 2026 Current Year's Estimate -1.433
Last Quarter’s Earnings -0.405 Median PE on CY Estimate N/A
Year Ago Earnings -1.545 Next Fiscal Year Estimate -1.065
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 4 2
Mean Estimate -0.33 -0.36 -1.43 -1.07
High Estimates -0.21 -0.23 -0.91 -0.98
Low Estimate -0.41 -0.44 -1.65 -1.15
Coefficient of Variance -32.36 -31.55 -24.45 -11.29

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 6 6
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Pmv Pharmaceuticals Inc - PMVP

Date Name Shares Transaction Value
Oct 28, 2025 OrbiMed Advisors Private Equity 4,975,291 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.52 per share 7,562,442.32
Mar 6, 2025 David H. Mack President and CEO; Director 800,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Deepika Jalota Chief Development Officer 300,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Michael Carulli Chief Financial Officer 265,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Pmv Pharmaceuticals Inc in the News